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Background: Acute kidney injury (AKI) complicating severe Plasmodium falciparum malaria occurs in up to 40% of
adult patients. The case fatality rate reaches 75% in the absence of renal replacement therapy (RRT). The precise
pathophysiology of AKI in falciparum malaria remains unclear. Histopathology shows acute tubular necrosis with
localization of host monocytes and parasitized red blood cells in the microvasculature. This study explored the
relationship of plasma soluble urokinase-type plasminogen activator receptor (suPAR), as a proxy-measure of
mononuclear cell activation, and plasma P. falciparum histidine rich protein 2 (PfHRP2), as a measure of sequestered
parasite burden, with AKI in severe malaria.
Methods: Admission plasma suPAR and PfHRP2 concentrations were assessed in Bangladeshi adults with severe
falciparum malaria (n = 137). Patients were stratified according to AKI severity based on admission creatinine
clearance.
Results: A total of 106 (77%) patients had AKI; 32 (23%), 42 (31%) and 32 (23%) were classified into ‘mild, ‘moderate’
and ‘severe’ AKI groups, respectively. Plasma suPAR and PfHRP2 concentrations increased with AKI severity (test-for-
trend P <0.0001) and correlated with other markers of renal dysfunction. Admission plasma suPAR and PfHRP2
concentrations were higher in patients who later required RRT (P <0.0001 and P = 0.0004, respectively). In a
multivariate analysis, both increasing suPAR and PfHRP2 were independently associated with increasing urine
neutrophil gelatinase-associated lipocalin concentration, a marker of acute tubular necrosis (β = 16.54 (95% CI 6.36-
26.71) and β = 0.07 (0.02-0.11), respectively).
Conclusions: Both sequestered parasite burden and immune activation contribute to the pathogenesis of AKI in
severe falciparum malaria.
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Acute kidney injury (AKI) complicating severe falcip-
arum malaria is an independent predictor of death in
both children and adults; without renal replacement
therapy (RRT) the adult case fatality rate reaches 75%
[1-3]. The incidence of AKI in severe malaria patients
varies across studies, but approaches 40% in adults and
10% in children under five years old [4]. Both pre-renal
(hypovolemia) and intrinsic renal factors can contribute;
two thirds of adults present with anuria or oliguria [2,4].
Histopathology shows acute tubular necrosis (ATN) hy-
pothesized to be caused by the observed sequestration of
parasitized red blood cells (PRBCs) and accumulation of
mononuclear cells in both glomerular and peritubular
capillaries [5-7]. However, the relative contribution of
each of these mechanisms cannot be assessed from post-
mortem studies.
Plasmodium falciparum histidine-rich protein 2 (PfHRP2)
is released in distinct amounts at the moment of schizont
rupture and is quantitatively related to parasite density
[8,9]. The plasma concentration of PfHRP2 estimates total
body P. falciparum burden, including the sequestered bio-
mass that causes obstructed microcirculatory flow in vital
organs. Unlike the peripheral parasitaemia level, plasma
PfHRP2 concentration correlates strongly with disease se-
verity and outcome [10-12].
Plasma soluble urokinase–type plasminogen activator
receptor (suPAR) reflects the systemic level of cell surface
urokinase-type plasminogen activator receptor (uPAR) ex-
pression, and has been proposed as a marker of immune
activation via modulation of mononuclear cell adhesion
and migration [13-15]. Cell-bound uPAR is expressed on
several cell types including activated lymphocytes, mono-
cytes, neutrophils, macrophages, vascular endothelial cells,
and kidney podocytes [14,15]. In African children with
acute malaria, plasma suPAR concentrations are elevated
and associated with higher mortality [16,17]. suPAR has
not been assessed previously in adults with severe falcip-
arum malaria.
Neutrophil gelatinase-associated lipocalin (NGAL) is se-
creted predominantly in damaged distal tubular renal epi-
thelial cells prior to neutrophil activation, and is an early
marker of renal tubular cell damage [18-20]. NGAL con-
centration is more reliable as a measure of kidney injury
than creatinine as it is less dependent on pre-renal factors
[18-20]. Upregulation of NGAL in renal tubule cells may
be induced by local release of cytokines from monocytes
in the microcirculation after ischemic injury [19].
The relationship between plasma suPAR, as a proxy-
measure of mononuclear cell immune activation, and
plasma PfHRP2, as a measure of sequestered parasite
burden, with AKI in adult patients with falciparum mal-
aria was assessed in this study. Severity of kidney dys-
function and damage was measured quantitatively bycreatinine clearance and urine NGAL (a marker of acute
tubular necrosis), respectively. Since kidney failure in se-
vere malaria is a consequence of severe ATN, severe kid-
ney tubular damage was assessed qualitatively by RRT
requirement.
Methods
Study design and patients
The study was an analysis of a subset of patients en-
rolled in two clinical trials assessing N-acetylcysteine
(2003–2005) and levamisole (2006–2010) as adjuvant
therapy in severe falciparum malaria [21,22]. Of the 141
severe malaria patients enrolled in these two studies, all
patients who had suPAR levels measured were included
in this analysis (N = 137 out of 141). Both studies were
conducted at Chittagong Medical College Hospital,
Bangladesh, a 1,000-bed tertiary referral hospital with
limited facilities for intensive care and RRT. Malaria
transmission in this area is seasonal with peak transmis-
sion from June to August. This analysis builds on work
presented from this cohort in 2011 [23]. Informed con-
sent was obtained from each patient or designated family
member. The Ministry of Health in Bangladesh, and Ox-
ford Tropical Research Ethics Committee (OXTREC)
granted ethical approval for both studies (registration
numbers: ISRCTN20156397 and ISRCTN27232551).
Adults (≥16 years) with slide-confirmed severe P. fal-
ciparum malaria were recruited. Criteria for severe mal-
aria included: coma (Glasgow Coma Score <11), shock
(systolic blood pressure (SBP) <80 mmHg with cool ex-
tremities), severe anaemia (haematocrit <20% plus para-
sitaemia >100,000/μl), severe jaundice (total bilirubin
>3.0 mg/dL plus parasitaemia >100,000/μl), hyperparasi-
taemia (peripheral asexual stage parasitaemia >10%), acid-
osis (venous bicarbonate <15 mmol/L), hyperlactataemia
(venous lactate >4 mmol/L), hypoglycaemia (blood glu-
cose <40 mg/dL), convulsions (≥ two in 24 hours), pul-
monary oedema, and/or renal failure (serum creatinine
>3 mg/dL).
Patients were treated with parenteral artesunate (Guilin
No 2 Pharmaceuticals, China) and managed according to
WHO treatment guidelines [24]. Supportive treatment, in-
cluding fluid resuscitation, was provided according to the
treating physician’s clinical judgment. RRT with haemodi-
alysis or peritoneal dialysis was not available for all pa-
tients due to limited resources. Additional treatments
have been previously described [21,22].
Study procedures
On enrolment, a complete medical history and examin-
ation were performed, and venous blood and urine col-
lected. Admission venous sodium, potassium, chloride,
glucose, blood urea nitrogen, haemoglobin, haematocrit,
pH and bicarbonate were assessed using a portable,
Plewes et al. Malaria Journal 2014, 13:91 Page 3 of 10
http://www.malariajournal.com/content/13/1/91handheld analyzer (iSTAT, Abbott, Illinois, USA). Per-
ipheral parasitaemia was assessed on admission and
every six hours until parasite clearance, defined as two
consecutive negative blood films. Plasma, serum and
urine samples were processed and stored at −80°C for
further analysis in Bangkok, Thailand and Amsterdam,
the Netherlands. The time and indication for RRT was
recorded.
Biomarker analysis
Plasma suPAR concentrations were measured using
suPARnostic™ ELISA (ViroGates, Copenhagen, Denmark),
according to the manufacturer’s instructions. Specimens
were diluted to read within the calibration curve defined
by quantitative standards. Reported results are the mean
suPAR concentration (ng/ml) of duplicate wells for each
specimen. Urine NGAL concentrations were measured
using Human Lipocalin-2/NGAL ELISA (R&D Systems,
Abingdon, UK) according to the manufacturer’s instruc-
tions. Multiple dilutions were tested in duplicate. The final
urine NGAL concentration (pg/ml) was normalized to
urinary creatinine and expressed as pg/mg of creatinine
(uNGAL/Ucr). Plasma PfHRP2 was assessed by commer-
cial sandwich ELISA (Celisa, Cellabs, Sydney, Australia),
according to the manufacturer’s instructions with minor
modifications [9]. Pooled reference plasma from 20
subjects with parasitaemia >200,0000/μl was calibrated
to purified PfHRP2 standard curves (kindly provided by
D Sullivan, John Hopkins School of Public Health,
Baltimore, USA). Concentrations in duplicate plasma
dilutions (1/25 to 1/3,125 in PBS/0.01%Tween) were de-
termined according to the linear component of the
standard curve. Cases where duplicates differed by more
than 50% were re-assayed.
Acute kidney injury
AKI was defined by the estimated creatinine clearance,
which is an accepted surrogate of kidney function mea-
sured by the glomerular filtration rate (GFR). Severity of
AKI was classified as mild, moderate or severe dysfunc-
tion based on admission creatinine clearance (CrCl):
mild (CrCl = 60–89.9 ml/min), moderate (CrCl = 30–
59.9 ml/min) and severe (CrCl <30 ml/min). No AKI
was defined as CrCl ≥90 ml/min. CrCl was calculated
using the Cockcroft-Gault formula [25]. No patient in-
cluded in the analysis had a history of renal disease.
Urine NGAL normalised to urine creatinine was used in
this analysis as a biomarker for kidney damage, specific-
ally acute tubular necrosis.
Indication for renal replacement therapy
Three clinicians (JH, PC and AMD) blinded to suPAR
and PfHRP2 results, independently reviewed each pa-
tient file to determine whether patients met pre-definedcriteria for RRT: hyperkalaemia (K >5.5 mmol/L), acid-
osis (pH <7.35, venous bicarbonate <15 mmol/L), fluid
overload refractory to diuretics, uncontrolled seizures,
pericarditis or rapid deterioration of renal function [23].
RRT was only deemed necessary in the setting of con-
comitant renal impairment (BUN >30 mmol/L or cre-
atinine >200 μmol/L), as adults with severe malaria may
have the above complications in the absence of AKI [23].
Statistical analysis
Differences between AKI groups (mild, moderate, severe
or no AKI) were compared by Student’s t-test and Mann–
Whitney-U test for normally and non-normally distrib-
uted variables, respectively. Data were transformed to
achieve a normal distribution where possible. A non-
parametric test-for-trend, which is an extension of the
Wilcoxon rank-sum test, was used to identify increasing
or decreasing associations with AKI severity. Correlations
between variables were assessed using Pearson’s correl-
ation coefficient. A robust regression model was con-
structed to assess the contributions of suPAR, PfHRP2,
suPAR x PfHRP2 interaction, age and SBP to the variation
in uNGAL/Ucr. Age and SBP were included in the model
as they are well-established risk factors for kidney injury.
There were no significant interactions between CrCl and
suPAR, nor CrCl and PfHRP2, therefore these terms were
not included in the models. To assess the relationship of
the same independent variables with the indication for
RRT, a logistic model with stepwise exclusion of non-
significant covariates was used. Improved model fit with
the inclusion of the interaction term was confirmed using
the likelihood ratio test. A P value of less than 0.05 was
considered significant. Statistical software used were
STATA/IC 12.0 (STATA, TX, USA), and Prism 6 for Mac
OS X (Graphpad Software, CA, USA).
Results
One-hundred and thirty-seven adults with severe falcip-
arum malaria were included in this analysis (Figure 1).
Baseline characteristics
Baseline characteristics and patient outcomes are shown
in Table 1. AKI was present in 106 patients (77%), of
whom 32 (23%), 42 (31%) and 32 (23%) were classified
as having mild, moderate and severe AKI, respectively.
AKI classification using the WHO definition (creatinine
>3 mg/dL) [24] rather than estimated CrCl, failed to
identify 11 (34%) patients in the severe AKI group.
These 11 patients had a geometric mean CrCl of 25 ml/
min, and 5/11 (45%) required RRT. The WHO definition
of AKI failed to identify 41/42 (98%) patients with moder-
ate AKI (geometric mean CrCl 42 ml/min), of those 13/41
(32%) required RRT. There was unanimous consensus
among three independent physicians on 39 patients (28%)
Figure 1 Consort diagram. After enrolment to the studies, patients admitted to Chittagong Medical College Hospital had blood and urine
samples collected. Plasma and urine biomarkers were measured and correlated with the renal diagnosis and the subsequent hospital course. One
patient with no AKI diagnosis on admission developed progressive renal impairment despite conservative measures and required RRT; this patient
presented in deep coma with hyperlactataemia. AKI = acute kidney injury; RRT = renal replacement therapy.
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RRT for logistical reasons. Two patients received haemo-
dialysis and 17 patients received peritoneal dialysis within
48 hours of admission. The most frequent indication for
RRT was acidosis (Table 2). Of the 19 patients who re-
ceived RRT, eight (42%) patients died; of the 20 patients
who met criteria for RRT but could not receive it, 15 pa-
tients died (75%). The overall case fatality rate was 53/137
(39%); 50/53 (94%) had cerebral malaria, 33/53 (62%) had
moderate or severe AKI, 35/53 (66%) had hyperlactatae-
mia, and 33/53 (62%) had severe acidosis.
Increasing severity of AKI correlated with increasing
age, and decreasing SBP and haematocrit (test-for-trend
p = 0.003, 0.048 and 0.011, respectively). Direct and in-
direct bilirubin increased and all measures of acid–base
status (lactate, base deficit, bicarbonate, pH, pCO2)
worsened with increasing kidney injury severity (test-for-
trend p <0.001).
Plasma soluble urokinase-type plasminogen activator
receptor, Plasmodium falciparum histidine rich protein-2
and acute kidney injury
Unlike peripheral parasitaemia, admission plasma PfHRP2
increased with worsening kidney function (test-for-trend
p <0.001, Figure 2). Plasma PfHRP2 increased with both
increasing creatinine (r = 0.49, P <0.001) and increasing
uNGAL/Ucr (r = 0.29, P <0.002) (Figure 3A-B). Peripheral
parasitaemia had a borderline correlation with serum
creatinine (r = 0.17, P = 0.05). Admission plasma suPAR
increased with increasing AKI severity (test-for-trend
p <0.001, Figure 2). There was a strong positive correlation
between suPAR and both creatinine (r = 0.51, P <0.001) and
uNGAL/Ucr (r= 0.38, P <0.001) (Figure 3C-D).
Plasma suPAR strongly correlated with PfHRP2 (r =
0.54, P <0.001); the interaction term (suPAR × PfHRP2)
also increased with both increasing creatinine (r = 0.58,
P <0.0001), increasing uNGAL/Ucr (r = 0.38, P <0.0001)
and AKI severity (test-for-trend p <0.0001). This wasfurther evaluated using linear regression with uNGAL/
Ucr as the dependent variable, representing acute tubu-
lar necrosis. In the univariate analysis suPAR, PfHRP2
and suPAR x PfHRP2 were significantly associated with
a higher concentration of uNGAL/Ucr (Table 3). Multi-
variate analysis showed that only plasma suPAR and
PfHRP2 were independently associated with higher
uNGAL, predicting 18% of the variation in uNGAL/Ucr
concentrations (R2 = 0.18; Table 3).
Plasma suPAR and PfHRP2 concentrations were higher
in patients requiring RRT (P <0.001, Figure 4). Logistic re-
gression was performed to further evaluate this rela-
tionship with RRT as the binary dependant variable,
representing severe tubular damage in severe malaria. In
univariate logistic analysis, increased suPAR, PfHRP2 and
suPAR x PfHRP2 were associated with increased odds for
RRT requirement (Table 4). In a stepwise, multivariate, lo-
gistic regression model, increasing plasma suPAR, PfHRP2
and age increased the odds of RRT requirement (R2 =
0.27; Table 4).
Relationship between plasma soluble urokinase-type
plasminogen activator receptor, Plasmodium falciparum
histidine rich protein-2 and mortality
Plasma suPAR and PfHRP2 concentrations were not sig-
nificantly higher in patients who died compared with
those who survived: 29.03 (25.38-33.22) versus 25.57
(23.27-28.10) ng/ml for suPAR (P = 0.12) and 1,685
(1,162-2,444) versus 1,629 (1,185-2,237) for PfHRP2
(P = 0.89). Plasma suPAR and PfHRP2 were significantly
elevated in patients who were acidotic (base deficit
>3.3 mmol/L) compared to those who were not: 29.63
(27.07-32.44) versus 20.67 (18.02-23.71) ng/ml for suPAR
(P <0.001) and 2,025 (1,569-2,613) versus 816 (469–
1,420) for PfHRP2 (P = 0.001). Standard base deficit
was significantly elevated in patients who died com-
pared to survivors; mean (SD), 11.8 (7.5) versus 6.5 (5.1)
(P <0.001).
Table 1 Baseline characteristics by acute kidney injury severity and clinical outcome
Variable Total No AKI Mild AKI Moderate AKI Severe AKI Test-for-trend
(n = 137) (n = 31) (n = 32) (n = 42) (n = 32)
Age (years)a 35 (23–45) 26 (18–35) 33 (25–40) 35 (21–50) 40 (28–48) 0.003
Malesc 110 (80) 27 (87) 27 (84) 30 (71) 26 (81) 0.301
Clinical
SBP (mmHg) 111 (19) 116 (15) 113 (20) 108 (20) 107 (21) 0.048
RR (breaths/min)b 31 (30–33) 29 (27–30) 34 (31–37) 32 (29–34) 32 (28–35) 0.239
GCS (#/15)a 8 (6–11) 8 (7–10) 8 (5–10) 9 (6–11) 9 (5–12) 0.937
Laboratory
HCT (%) 30 (8) 34 (7) 30 (9) 29 (8) 29 (8) 0.011
Parasitaemia 73209 46723 33560 174140 78018 0.070
(#/μL)b (50362–106419) (19688–110884) (11984–93981) (120635–251377) (36814–165340)
Creatinine 1.53 0.69 1.11 1.75 3.80 <0.001
(mg/dL)b (1.37–1.72) (0.63–0.76) (1.03–1.21) (1.60–1.91) (3.26–4.43)
BUN (mg/dL)b 42 (37–48) 21 (18–25) 27 (23–32) 57 (50–65) 88 (73–105) <0.001
CrCl 50.6 123.3 72.5 41.7 19.3 <0.001
(ml/min)b (44.9–57.0) (112.8–134.8) (69.8–75.3) (39.0–44.5) (17.0–21.8)
Potassium (mmol/L) 4.4 (1.0) 4.0 (0.7) 4.4 (1.1) 4.4 (0.7) 4.6 (1.4) 0.031
Sodium (mmol/L) 133 (7) 129 (7) 134 (5) 133 (8) 133 (6) 0.069
Albumin (g/L) 29 (5) 31 (5) 30 (4) 28 (5) 27 (6) <0.001
Total bilirubin (mg/dL)b 4.5 (3.8–5.4) 4.1 (2.8–5.9) 3.1 (2.3–4.1) 4.9 (3.5–6.7) 6.7 (4.7–9.6) 0.011
Direct bilirubin (mg/dL)b 1.8 (1.5–2.2) 1.2 (0.8–2.0) 1.1 (0.8–1.5) 2.2 (1.5–3.2) 3.4 (2.2–5.2) <0.001
ALT (U/L)b 30 (25–36) 22 (17–28) 30 (21–43) 36 (25–51) 34 (23–51) 0.064
Base excess (mmol/L) −9 (7) −4 (4) −5 (4) −11 (7) −13 (7) <0.001
Bicarbonate (mmol/L) 17 (5) 21 (4) 19 (4) 14 (5) 14 (4) <0.001
pH 7.37 (0.13) 7.42 (0.08) 7.42 (0.09) 7.35 (0.12) 7.30 (0.17) <0.001
pCO2 (mmHg) 28 (7) 32 (6) 29 (7) 25 (8) 26 (7) <0.001
Lactate (mmol/L)b 5.1 (4.6–5.6) 4.3 (3.7–5.1) 3.9 (3.2–4.7) 7.1 (6.0–8.3) 4.9 (3.8–6.4) 0.029
Biomarkers
HRP2 1649 678 1413 2419 2833 <0.001
(ng/ml)b (1297–2096) (397–1156) (967–2064) (1715–3413) (1648–4872)
uNGAL/Ucr 1262 750 1,012 1281 2549 <0.001
(pg/mg cr)b (1097–1451) (589–956) (745–1376) (1066–1541) (1943–3345)
Outcomes
RRT indicatedc 39 (28) 1 (3) 2 (6) 14 (33) 22 (69) <0.001
Deathc 53 (39) 12 (39) 8 (25) 19 (45) 14 (44) 0.333
All values are mean (SD) unless otherwise specified; amedian (IQR), bgeometric mean (95% CI), cnumber (%). P <0.05 using test-for-trend; significant in bold.
AKI = acute kidney injury; SBP = systolic blood pressure; RR = respiratory rate; GCS = Glasgow Coma Scale; HCT = haematocrit; BUN = blood urea nitrogen; CrCl =
creatinine clearance; ALT = alanine transaminase; pCO2 = venous partial pressure carbon dioxide; HRP2 = Plasmodium falciparum histidine rich protein 2; suPAR =
soluble urokinase-type plasminogen activator receptor; uNGAL/Ucr = urine neutrophil gelatinase-associated lipocalin corrected for urine creatinine; RRT = renal
replacement therapy.
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In this study of adult patients with severe falciparum
malaria, admission plasma suPAR and PfHRP2 were
strongly and independently associated with AKI, and a
later requirement for RRT. As suPAR is an indirectmeasure of mononuclear cell activation, and PfHRP2 a
measure of sequestered parasite biomass, these results
suggest that both mechanisms contribute to the patho-
genesis of AKI. These findings are concordant with post-
mortem renal histopathological findings in patients with
Table 2 Indication for renal replacement therapy
Indication Number
Renal impairment and acidosis 20
Renal impairment and hyperkalaemia 0
Renal impairment, acidosis and hyperkalaemia 6
Renal impairment, acidosis and convulsions 2
Renal impairment, acidosis, hyperkalaemia and convulsions 3
Worsening renal function despite conservative measures 5
Worsening renal function and convulsions 1
Renal impairment and pulmonary oedema 1
Renal impairment, acidosis and pulmonary oedema 1
Total 39
Figure 2 Scatterplots of cohort stratified by admission acute
kidney injury severity. (A) Plasma soluble urokinase–type
plasminogen activator receptor (suPAR), and (B) plasma HRP2
concentrations. Concentrations for both suPAR and HRP2 increased
with increasing severity of AKI (test-for-trend P <0.0001). Geometric
mean and 95% confidence intervals displayed. AKI = acute kidney
injury; HRP2 = P. falciparum histidine rich protein 2.
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and mononuclear cell infiltration in glomerular and peri-
tubular capillaries [6].
Multivariate regression analysis showed that plasma
PfHRP2 independently correlated with uNGAL, and a
requirement for RRT. Histopathology of falciparum
malaria-associated AKI shows a significant increase in
sequestration among patients with a creatinine >3 mg/
dL, which defines AKI according to WHO malaria treat-
ment guidelines [6]. Overall, disease severity and the se-
verity of metabolic acidosis have also been shown to
correlate strongly with plasma PfHRP2 concentrations
[9-12,26]. PfHRP2 was significantly elevated in patients
who were acidotic. Peripheral parasitaemia does not re-
flect the pathogenic-sequestered parasite burden that
causes impaired microvascular flow, and the correlation
between parasitaemia and total parasite burden is vari-
able. This might explain why the presented results con-
trast with other studies, in that an association between
hyperparasitaemia and AKI severity was not found
[6,27,28]. However, plasma PfHRP2, representing the
total parasite biomass including the sequestered para-
sites, strongly correlated with AKI defined by either
WHO or CrCl classification. The correlation between
PfHRP2 and creatinine was also stronger than the cor-
relation between peripheral parasitaemia and creatinine.
Sequestered PRBCs occluding the renal microcirculation
may explain why increasing the overall renal blood flow
in severe malaria does not result in a change in renal
oxygen consumption [29]; as only patent vessels free of
sequestered PRBCs would continue to be perfused and
PRBC occluded vessels would not be recruited.
Plasma suPAR increased with deteriorating renal func-
tion defined by CrCl classification and WHO criteria,
urine NGAL and independently predicted RRT require-
ment. Plasma suPAR is positively correlated with cre-
atinine in patients with Hantavirus and critically ill
patients, and inversely correlated with estimated glom-
erular filtration rate (GFR) in chronic kidney disease[30-33]. Histology of brain tissue from cerebral malaria
patients shows an increase in uPAR expression in
macrophage and endothelial cells spatially limited to
areas with PRBCs sequestered in the microvasculature
[34]. This is the first time elevated suPAR has been
shown to be associated with kidney injury and dysfunc-
tion in malaria. This supports that the histopathological
mononuclear cell accumulation in glomerular and peri-
tubular capillaries contribute to the acute tubular necro-
sis in patients with a creatinine above and below 3 mg/
dL, despite a difference in observed sequestration of
PRBCs. It is possible that sequestration acts as an endo-
thelial nidus and subsequent positive feedback loop for
increased suPAR-mediated mononuclear cell recruit-
ment and immune activation resulting in more severe
tubular damage. Cell-to-cell contact between endothelial
cells and monocytes increases suPAR release [14] and
suPAR subsequently recruits more monocytes via its
Figure 3 Correlations of variables involved in acute kidney injury. Correlations of variables proposed to be involved in the pathogenesis of
acute tubular necrosis in malaria associated AKI with marker of renal dysfunction (creatinine) and marker of kidney damage (uNGAL/Ucr). Pearson’s
correlation coefficient between plasma P. falciparum histidine rich protein 2 (HRP2) and (A) serum creatinine; and (B) uNGAL/Ucr. Pearson’s correlation
coefficient between suPAR and (C) serum creatinine; and (D) uNGAL/Ucr. All variables were log transformed (log10) for correlation plots and Pearson’s
analysis. suPAR = soluble urokinase–type plasminogen activator receptor; uNGAL/Ucr = urine neutrophil gelatinase-associated lipocalin corrected for
urine creatinine.
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rupture, haemozoin (malaria pigment) acts as antigen
to activate monocytes resulting in release of pro-
inflammatory cytokines and chemokines [37,38]. This
could initiate a positive feedback loop since TNF-α in-
creases expression of uPAR on monocytes resulting in ac-
celerated cleavage of suPAR and consequent monocyte
recruitment [35,38]. Indeed, mononuclear cells loaded
with pigment are observed in glomerular and peritubular
microvessels on histopathology [6]. As elevated suPAR
concentrations have not been shown to be directly pro-Table 3 Linear regression analysis of variables contributing to
malaria
Univariate analysis
Variable β (95% CI)a P
suPAR 21.57 (12.20-30.95) <0
PfHRP2 0.11 (0.06-0.15) <0
suPAR x PfHRP2 0.002 (0.001-0.003) <0
SBP 0.16 (−8.62-8.94) 0.9
Age −12.02 (−25.32-1.28) 0.0
aRegression coefficient (β) with 95% confidence intervals (CIs) showing the estimated i
(uNGAL/Ucr pg/mg of creatinine) predicted by 1 unit increases in the independent (prinflammatory [39], the accumulation of activated monocytes
releasing cytokines are the likely effectors contributing
to renal tubular cell damage in severe malaria.
In this study there was no association between suPAR
and mortality, which contrasts with a study of African
children with malaria where increased suPAR concentra-
tions were associated with poor clinical outcomes [16].
This may be because there was a low mortality rate (2%)
in the African study, suggesting less severe disease. The
entire cohort presented here was severely ill with a high
mortality rate and higher suPAR concentrations comparedurine NGAL/Ucr variability in patients with severe
Multivariate model (R2 = 0.18)
β (95% CI)a P
.001 16.54 (6.36-26.71) 0.002




ncrease in the urine concentration of NGAL (pg/ml) corrected for urine creatinine
edictor) variables using robust regression analysis. Significant in bold.
Figure 4 Scatterplots of cohort stratified by renal replacement
therapy requirement. (A) Plasma suPAR, and (B) plasma HRP2.
Biomarkers were log transformed (log10) for normality. T-tests were
performed for comparisons between groups. RRT = renal replacement
therapy; suPAR = soluble urokinase–type plasminogen activator
receptor; HRP2 = P. falciparum histidine rich protein 2.
Table 4 Logistic regression analysis of variables predicting re
Univariate analysis
Variable OR (95% CI)b P
suPAR 1.07 (1.04-1.11) <0
PfHRP21/2 1.03 (1.02-1.05) <0
suPAR1/2 x PfHRP21/2 1.01 (1.00-1.01) <0
SBP 1.01 (0.99-1.03) 0.5
Age 1.02 (0.99-1.05) 0.1
bOdds ratios (OR) with 95% CIs were determined for renal replacement therapy (RR
variables are shown in bold. PfHRP2 was square root transformed to normalize skew
OR = odds ratio; CI = confidence intervals; uNGAL/Ucr = urine neutrophil-associated
plasminogen activator receptor; PfHRP2 = P. falciparum histidine rich protein 2; SBP
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http://www.malariajournal.com/content/13/1/91to the African study [16]; including uncomplicated malaria
patients in this analysis may have shown an association
between suPAR concentration and mortality.
There are limitations to this study. Both suPAR and
HRP2 measured in the plasma are not organ specific
markers of monocyte activation and sequestration, re-
spectively. However, kidney specific markers of these
phenomena currently do not exist. The justification of
the analyses of plasma suPAR and HRP2 is based on the
histopathology that has shown sequestration of PRBCs
and mononuclear cell infiltration in the kidney. Since
suPAR was measured in plasma, the concentrations
measured likely represent production by activated host
immune cells, in particular mononuclear cells, however
endothelial sources could also contribute. As suPAR has
renal clearance, elevated plasma levels can be a conse-
quence of reduced GFR [31,33]. However, in the mul-
tiple regression models, interaction terms of CrCl,
suPAR and PfHRP2 did not reveal a significant contribu-
tion, and the association between suPAR and indication
for RRT was also found in patients presenting without
AKI on admission. It has been shown that plasma HRP2
half life is not correlated with biochemical evidence of
kidney dysfunction [9]. Urine NGAL as a biomarker for
renal tubular damage has limitations, as its excretion de-
pends on the timing in relation to the initial renal injury
[40]. However, NGAL is an ‘induced’ biomarker, thus ex-
cretion is continued with ongoing renal stress [40].
Using renal biopsy as a reference standard for ATN was
not feasible or ethically indicated in this study, so RRT
requirement was used as an alternative endpoint. Finally,
the sample size in this study was relatively small and pa-
tient data were reviewed retrospectively. However, this
assessment was done according to pre-defined criteria
and three independent specialist physicians were in full
agreement.
Conclusions
This study suggests that parasite sequestration and im-
mune activation contribute to the pathogenesis of AKI in
severe falciparum malaria. Early diagnosis of falciparumnal replacement therapy in patients with severe malaria
Multivariate model (R2 = 0.27)
OR (95% CI)b P
.001 1.07 (1.03-1.12) 0.002
.001 1.02 (1.00-1.04) 0.026
.001 — —
22 — —
23 1.05 (1.01-1.10) 0.010
T) associated with 1-U changes in the independent variables. Significant
ed data. Significant in bold.
gelatinase lipocalin corrected for urine creatinine; suPAR = soluble urokinase
= systolic blood pressure.
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http://www.malariajournal.com/content/13/1/91malaria and treatment with artemisinin-based anti-
malarials will rapidly eliminate ring-staged parasites, pre-
venting their microvascular sequestration in vital organs,
including the kidney. Deeper understanding of the immu-
nopathological mechanisms underlying AKI in severe
malaria might reveal novel, targeted, treatment options
to further prevent this common and life-threatening
complication.
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